Lauren Dembeck, PhD

Contributing Writer https://www.cancertherapyadvisor.com

Lauren Dembeck is a freelance science and medical writer and a contributing author for the Haymarket Medical Network. She holds a BS in biology and a BA in foreign languages from West Virginia University and a PhD in genetics from North Carolina State University. Prior to freelance writing, Lauren was a postdoctoral researcher at the Okinawa Institute of Science and Technology in Japan, where she studied developmental neurobiology. You can find more of her writing at https://laurendembeck.com/

All articles by Lauren Dembeck, PhD

CRS and HIPEC appear to have promising data when used in the optimal patient population.

Lymphoma

Intensive Chemotherapy Tolerable, Efficacious in HIV-Associated Burkitt Lymphoma

Lauren Dembeck, PhD

December 16, 2020

Among patients with HIV-associated Burkitt lymphoma, intensive regimens containing rituximab may be linked to favorable survival outcomes.

A person holding 2 white pills in their hand.

Lymphoma

Mantle Cell Lymphoma: Long-Extending Remissions With Lenalidomide, Rituximab

Lauren Dembeck, PhD

December 16, 2020

Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.

Treating a patient that has tested positive for coronavirus.

Hematologic Cancers

Mortality Risk in Patients With Hematologic Malignancies and COVID-19

Lauren Dembeck, PhD

December 16, 2020

Investigators assessed mortality rates and other outcomes in patients with hematologic malignancies and COVID-19 infection.

Hematologic Cancers

Factors Affecting Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Hematologic Malignancies

Lauren Dembeck, PhD

December 10, 2020

Among patients with blood cancers, genetic variant profiles may negatively affect allo-HSCT outcomes including leukemia-free survival and acute GVHD.

Light micrograph of a blood smear from a patient with polycythemia vera.

Multiple Myeloma

Mortality Rates, Diverse Causes of Death in Polycythemia Vera

Lauren Dembeck, PhD

December 10, 2020

Study results presented at the annual meeting of the American Society of Hematology suggest that the estimated 4-year mortality rate among patients with polycythemia vera is more than 10%, and that causes of death vary.

Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastase

Multiple Myeloma

Personalized Diagnostic Model Differentiates Myelodysplastic Syndromes From Other Myeloid Malignancies

Lauren Dembeck, PhD

December 10, 2020

A geno-clinical model used mutational data and peripheral blood counts to accurately distinguish myelodysplastic syndromes from other myeloid malignancies.

Hematologic Cancers

Notable Variation Exists in the Treatment of Serious VTE Events in Pediatric Leukemia

Lauren Dembeck, PhD

November 6, 2020

There might be notable variations among hematology, oncology, and bone marrow transplant practitioners when treating thrombotic events in children with leukemia.

Increased travel burden is associated with a decreased likelihood of receiving adjuvant chemotherapy

Hematologic Cancers

Unfitness Criteria Predict Early Mortality After Intensive Chemotherapy in Acute Myeloid Leukemia

Lauren Dembeck, PhD

October 22, 2020

The Ferrara criteria are widely used to identify patients with AML who are most suitable for intensive chemotherapy, though the accuracy is unknown.

Lymphoma

Modern Radiation Therapy Limits Radiation Doses to Organs at Risk in Hodgkin Lymphoma

Lauren Dembeck, PhD

October 20, 2020

Combined modality therapy for early-stage favorable HL yielded excellent outcomes and limited excess radiation doses to organs at risk.

Lymphoma

Brentuximab Vedotin Plus Nivolumab as Chemotherapy-Free Strategy for Hodgkin Lymphoma in Older Patients

Lauren Dembeck, PhD

October 19, 2020

Findings suggest that brentuximab vedotin plus nivolumab was well tolerated and active in older patients with previously untreated HL with comorbidities.

Next post in Lymphoma